Keywords
Pathogenesis
Treatment progress
Submitted : 2021-08-31
Accepted : 2021-09-15
Published : 2021-09-30
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a special and common clinical heart failure with left ventricular diastolic dysfunction. It has attracted much attention at home and abroad in recent years because of its high heterogeneity and complex pathogenesis. Compared with heart failure with reduced ejection fraction (HFrEF), HFpEF has complex clinical manifestations, many complications, limited clinical treatment, and poor prognosis. In recent years, the research on the pathogenesis and treatment of HFpEF has made certain progress, but there are no specific guidelines for clinical practice. By combing the latest research at home and abroad, the pathogenesis and treatment of HFpEF are systematically reviewed in order to provide a relevant basis for reference its clinical treatment.
References
Bozkur TB, 2018, What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines. Curr Cardiol Rep, 20(6): 39.
Ponikowski P, Voors AA, Anker SD, et al., 2016, 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail, 18(8): 891-975.
From AM, Borlaug BA, 2011, Heart Failure with Preserved Ejection Fraction: Pathophysiology and Emerging Therapies. Cardiovascular Therapeutics, 29: e6-e21.
Frangogiannis NG, 2014, The inflammatory Response in Myocardial Injury, Repair, and Remodelling. Nat Rev Cardiol, 11(5): 255-265.
Røe ÅT, Sjaastad I, Louch WE, 2017, Heart Failure with Preserved Ejection Fraction. Tidsskr Nor Laegeforen, 137(18).
Sato Y, Yoshihisa A, Oikawa M, et al., 2019, Prognostic Impact of Worsening Renal Function in Hospitalized Heart Failure Patients with Preserved Ejection Fraction: A Report From the JASPER Registry. J Card Fail, 25(8): 631-642. 10.1016/j.cardfail.2019.04.009
Yoon S, Eom GH, 2019, Heart Failure with Preserved Ejection Fraction: Present Status and Future Directions. Exp Mol Med, 51(12): 1-9
Upadhya B, Kitzman DW, 2020, Heart Failure with Preserved Ejection Fraction: New Approaches to Diagnosis and Management. Clin Cardiol, 43(2): 145-155. 10.1002/clc.23321
Borlaug BA, 2009, Treatment of Heart Failure with Preserved Ejection Fraction. Curr Treat Options Cardiovasc Med, 11: 79-87.
McDiarmid AK, Swoboda PP, Erhayiem B, et al., 2020, Effects of Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction. J Am Heart Assoc, 9(1): e011521.
Chandra A, Vaduganathan M, Lewis EF, et al., 2019, PARAGON-HF Investigators. Health-Related Quality of Life in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail, 7(10): 862-874. 10.1016/j.jchf.2019.05.015
Kjeldsen SE, von Lueder TG, Smiseth OA, et al., 2020, Medical Therapies for Heart Failure with Preserved Ejection Fraction. Hypertension, 75(1): 23-32. 10.1161/HYPERTENSIONAHA.119.14057
Martin N, Manoharan K, Thomas J, et al., 2018, Beta-Blockers and Inhibitors of the Renin-Angiotensin Aldosterone System for Chronic Heart Failure with Preserved Ejection Fraction. Cochrane Database Syst Rev, 6(6): CD012721.
Cleland JGF, Bunting KV, Flather MD, et al., 2018, Beta-Blockers for Heart Failure with Reduced, Mid-Range, and Preserved Ejection Fraction: An Individual Patient-Level Analysis of Double-Blind Randomized Trials. Eur Heart 39(1): 26-35.
Paulus WJ, van Ballegoij JJ, 2010, Treatment of Heart Failure with Normal Ejection Fraction: An Inconvenient Truth! J Am Coll Cardiol, 55: 526-37.
Anker SD, Butler J, Filippatos G, et al., 2020, EMPEROR-Preserved Trial Committees and Investigators. Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial. Eur J Heart Fail, 22(12): 2383-2392.
Yang Y, Xu C, Tang S, et al., 2020, Interleukin-9 Aggravates Isoproterenol-Induced Heart Failure by Activating Signal Transducer and Activator of Transcription 3 Signalling. Can J Cardiol, 36(11): 1770-1781.